Navigation Links
Medical Research in China Industry Research Report – Now Available from IBISWorld
Date:12/16/2012

San Francisco, CA (PRWEB) December 16, 2012

In 2012, the Medical Research industry in China is expected to generate $6.8 billion. Annualized growth over the past five years period has been about 14.3%. Over half of industry revenue is derived from government funding.

The Medical Research industry is beginning to mature and competition for government funds and private funds has increased. IBISWorld estimates that profitability is low in 2012 due to the high costs for medical research and commercialization difficulties. Profitability varies among different participants in the industry, however. Biotechnology companies tend to be profitable, while medical research institutes are more likely to suffer losses.

In 2012, the combined market share of the top four companies in the Medical Research industry in China – Chinese Academy of Sciences, WuXi AppTec, Shanghai Institute of Pharmaceutical Industry, and the Academy of Military Medical Sciences – is estimated at 19.7%. This low concentration level is due to the existence of a large number of non-profit medical research institutions and small-scale biotechnology companies. Non-profit medical research institutions rely heavily on government funding.

With increasing importance attached to research and development, the Medical Research industry in China is expected to develop steadily over the next five years. More research institutions are expected to restructure into for-profit enterprises or establish their own enterprises. Further, biotechnology companies will continue to increase in size, says IBISWorld.

For more information, visit IBISWorld’s Medical Research in China industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld
Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld Industry Report Key Topics

The Medical Research industry in China is engaged in basic and applied research and development in the medical and pharmaceutical fields. Enterprises include laboratories of medical research institutes, medical schools and biotech firms. The following research functions are not included in the industry: R&D activities by pharmaceutical or medical equipment manufacturing industries; research unrelated to the human body or human diseases; and the commercialization of medical research.

Industry Performance
Executive Summary
Key External Drivers
Current Performance
Industry Outlook
Industry Life Cycle
Products & Markets
Supply Chain
Products & Services
Major Markets
Globalization & Trade
Business Locations
Competitive Landscape
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Barriers to Entry
Major Companies
Operating Conditions
Capital Intensity
Key Statistics
Industry Data
Annual Change
Key Ratios

About IBISWorld Inc.
Recognized as the nation’s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10192043.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
3. CAM therapy combined with conventional medical care may improve treatment of lower back pain
4. Image share project gives patients and physicians anytime, anywhere access to medical images
5. Researchers determine vitamin D blood level for reducing major medical risks in older adults
6. Biomedical researchers receive Hartwell Foundation awards
7. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
8. Fitness in Middle Age Lowers Medical Costs Later: Study
9. Ben-Gurion U. and Cincinnati Childrens Hospital to develop pediatric-specific medical technologies
10. Gene Tests May Not Drive Patients to More Medical Care
11. University studies and career expectations of medical students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... Therapy continues to prove the safety and efficacy of HBOT in treating and ... across the US, points to research showing the similarities of the wounds to ...
(Date:8/23/2017)... TX (PRWEB) , ... August 23, 2017 , ... ... in the healthcare industry, made the 2017 Inc. 5000 with a three-year ... of the nation’s fastest-growing private companies and comprises the most comprehensive look at ...
(Date:8/23/2017)... ... August 23, 2017 , ... MobilityWorks ®, ... named to the 2017 Inc. 500|5000, an exclusive ranking of America’s fastest-growing private ... of 139 percent, marking the twelfth year that the company has been included ...
(Date:8/23/2017)... ... 23, 2017 , ... A new literature review ... points out that therapeutic modalities (physical therapy) is an important part of the ... a wider scope of physical therapy options is showing promising results and supports ...
(Date:8/22/2017)... ... August 22, 2017 , ... The old adage ... as simple as eating healthy foods. But this well-known piece of nutrition advice ... or breaking apart carbohydrates—depends not only on properties of the food but also ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), ... Michigan residents. Naloxone is available ... retail pharmacy, G-3320 Beecher Road. ... and Drug Administration, is intended to block or reverse ... and loss of consciousness. The medication is often carried ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
Breaking Medicine Technology: